Clinical Review Report: Buprenorphine extended-release injection (Sublocade)

Posted 10/23/2020 (updated 4/3/2024)

The objective of this report was to perform a systematic review of the beneficial and harmful effects of BUP-ER 100 mg and 300 mg for the management of moderate-to-severe OUD in adult patients who have been inducted and clinically stabilized on a transmucosal buprenorphine-containing product.